ArticleNanotheranostics2021
Cyclodextrin nanosponge for the GSH-mediated delivery of Resveratrol in human cancer cells.
Article in Nanotheranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Cyclodextrins as Multifunctional Platforms in Drug Delivery and Beyond: Structural Features, Functional Applications, and Future Trends.Molecules (Basel, Switzerland) · 2025Review
- Smart Drug Delivery Systems Based on Cyclodextrins and Chitosan for Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Nanosponges-road Less Explored Changing Drug Delivery Approach: An Explicative Review.Current pharmaceutical biotechnology · 2025Review
- Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025Review
- Cyclodextrin Nanosponges: A Revolutionary Drug Delivery Strategy.Pharmaceutical nanotechnology · 2024Review
- Biomimetic nanocarriers: integrating natural functions for advanced therapeutic applications.Beilstein journal of nanotechnology · 2024Article
- Review
- Glycolysis Inhibition of Autophagy Drives Malignancy in Ovarian Cancer: Exacerbation by IL-6 and Attenuation by Resveratrol.International journal of molecular sciences · 2023Article
- In vitro Antitumor Properties of Fucoidan-Coated, Doxorubicin-Loaded, Mesoporous Polydopamine Nanoparticles.Molecules (Basel, Switzerland) · 2022Article
- Formulation, Characterization, Anti-Inflammatory and Cytotoxicity Study of Sesamol-Laden Nanosponges.Nanomaterials (Basel, Switzerland) · 2022Article
- Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.Cellular and molecular life sciences : CMLS · 2022Review
- Nanosponges: An overlooked promising strategy to combat SARS-CoV-2.Drug discovery today · 2022Review
- Nanosponges for Drug Delivery and Cancer Therapy: Recent Advances.Nanomaterials (Basel, Switzerland) · 2022Review
- Design of a Lab-On-Chip for Cancer Cell Detection through Impedance and Photoelectrochemical Response Analysis.Biosensors · 2022Article
- Article
- Resveratrol activates CD8Frontiers in pharmacology · 2022Article
- Cyclodextrin-Based Nanosponges: Overview and Opportunities.Frontiers in chemistry · 2022Review
- Calorie Restriction for Cancer Prevention and Therapy: Mechanisms, Expectations, and Efficacy.Journal of cancer prevention · 2021Review
- Characteristics of P-Type and N-Type Photoelectrochemical Biosensors: A Case Study for Esophageal Cancer Detection.Nanomaterials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smart drug delivery systems are required for the site-specific drug targeting to enhance the therapeutic efficiency of a drug. Resveratrol (RV) is a polyphenolic compound with anti-cancer activity. However, its poor aqueous solubility and non-selectivity are the major challenges for its employment in cancer therapy. In this work, we present the synthesis of RV-loaded glutathione responsive cyclodextrin nanosponges (RV-GSH-NSs) to improve the therapeutic efficiency and selective delivery of RV. The drug loading and encapsulation efficiency were 16.12% and 80.64%, respectively. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.